Phosphorylation of PR by ERK in response to constitutively high levels of EGF/ErbB1 signaling, a condition present in some tumors, may limit the long-term effectiveness of progestin therapy in the treatment of endometrial cancer by down-regulating receptor levels. Here, PGR is linked to endometrial cancer.